|
|
|
| Study on proteomics of hepatocellular carcinoma cell based on iTRAQ technology |
| GUAN Yuanyue GAO Yuxue ZHUANG Yuan CHEN Dexi WANG Yanjun |
| Beijing Institute of Hepatology, Beijing You An Hospital, Capital Medical University, Beijing 100069, China |
|
|
|
Abstract Objective To screen the differentially expressed proteins between HepG2.2.15 cells with stable hepatitis B virus (HBV) expression and its parent HepG2 cells, the isotope tagging for relative and absolute protein quantitation (iTRAQ) technique was used. Methods The differential proteins in HepG2.2.15 cells and HepG2 cells were analyzed by iTRAQ technique, and the functional clustering and signaling pathway analysis of the differential proteins were performed by bioinformatics. Differential proteins were screened based on the cell difference factor (FC)≥ 1.2 and P ＜ 0.05 between the two groups. Kyoto encyclopedia of genes and genomes ( KEGG) and other analysis software were used for bioinformatics analysis of differential proteins. Results A total of 856 differential proteins were screened out in this study, among which 497 differentia proteins were up-regulated and 359 differential proteins were down-regulated. GO analysis showed that differential proteins were involved in biological processes including immune process and signal transduction and transport process. Most of the different protein components were distributed in cytoplasm and extracellular. The molecular functions of differential proteins mainly focus on receptor binding and metal ion binding. KEGG analysis revealed that differential proteins were mainly involved in the regulation of many cell biological functions, including drug metabolism, chemical carcinogenesis, cytochrome P450 metabolism of foreign bodies, and mitogen-activated protein kinase signaling pathways. Conclusion The differential proteins screening based on iTRAQ technology have not been previously associated with HBV replication, and may provide clues and an experimental basis for further exploration of HBV replication.
|
|
|
|
|
|
[1] 陈欢，杨燕卿，储君，等.HBV持续感染及其机制的研究进展[J].临床肝胆病杂志，2020，36（1）：174-177.
[2] Shih C，Yang CC，Choijilsuren G，et al. Hepatitis B Virus[J]. Trends Microbiol，2018，26（4）：386-387.
[3] 杨俊杰，鄢业鸿.抗病毒治疗对HBV相关性HCC影响的研究进展[J].广东医学，2019，40（24）：3489-3493.
[4] Liu L，Vo A，Liu G，et al. Distinct structural domains within C19ORF5 support association with stabilized microtubules and mitochondrial aggregation and genome destruction [J]. Cancer Res，2005，65（10）：4191-4201.
[5] Xie R，Nguyen S，Mckeehan WL，et al. Acetylated microtubules are required for fusion of autophagosomes with lysosomes [J]. BMC Cell Biol，2010，11：89.
[6] Xie R，Nguyen S，Mckeehan K，et al. Microtubule-associated protein 1S （MAP1S） bridges autophagic components with microtubules and mitochondria to affect autophagosomal biogenesis and degradation [J]. J Biol Chem，2011， 286（12）：10367-10377.
[7] Li W，Yue F，Dai Y，et al. Suppressor of hepatocellular carcinoma RASSF1A activates autophagy initiation and maturation [J]. Cell Death Differ，2019，26（8）：1379-1395.
[8] Liu P，de la Vega MR，Dodson M，et al. Spermidine Confers Liver Protection by Enhancing NRF2 Signaling Through a MAP1S-Mediated Noncanonical Mechanism [J]. Hepatology，2019，70（1）：372-388.
[9] Xu G，Jiang Y，Xiao Y，et al. Fast clearance of lipid droplets through MAP1S-activated autophagy suppresses clear cell renal cell carcinomas and promotes patient survival [J]. Oncotarget，2016，7（5）：6255-6265.
[10] Wang Y，Zhang S，Dang S，et al. Overexpression of microRNA-216a inhibits autophagy by targeting regulated MAP1S in colorectal cancer [J]. Onco Targets Ther， 2019， 12：4621-4629.
[11] Barbiero I，De Rosa R，Kilstrup-Nielsen C. Microtubules： A Key to Understand and Correct Neuronal Defects in CDKL5 Deficiency Disorder?[J]. Int J Mol Sci，2019，20（17）：4075.
[12] Vandin F，Clay P，Upfal E，et al. Discovery of mutated subnetworks associated with clinical data in cancer [J]. Pac Symp Biocomput，2012：55-66.
[13] Jiang X，Zhong W，Huang H，et al. Autophagy defects suggested by low levels of autophagy activator MAP1S and high levels of autophagy inhibitor LRPPRC predict poor prognosis of prostate cancer patients[J]. Mol Carcinog，2015，54（10）：1194-1204.
[14] 魏红山，李红敏，任慧，等.糖基因GLT25D2敲除小鼠的制备与基因型鉴定[J].中华实验和临床病毒学杂志，2013，27（6）：492-494.
[15] 刘燃，李红敏，任慧，等.Colgalt2-酶联免疫试剂盒的制备[J].中华实验和临床病毒学杂志，2014，28（6）：491-493.
[16] 张晓慧，郭乐乐，魏红山，等.糖基转移酶Colgalt2基因缺失对于对乙酰氨基酚导致的肝损伤的保护作用初探[J].中华肝脏病杂志，2021，29（1）：67-71.
[17] 董芳，张锦前，肖凡，等.HBV相关糖基转移酶Glt25D2的核苷酸单糖结合活性分析[J].中国病原生物学杂志，2011，6（2）：93-96.
[18] 董芳.糖基转移酶Glt25D2克隆、表达及与HBV包膜大蛋白间的关系研究[D].太原：山西医科大学，2009.
[19] Wang YP，Liu F，He HW，et al. Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus [J]. Antimicrob Agents Chemother，2010，54（5）：2070-2077.
[20] Wang YP，Zhao W，Xue R，et al. Oxymatrine inhibits hepatitis B infection with an advantage of overcoming drug-resistance [J]. Antiviral Res，2011，89（3）：227-231.
[21] Wright TL. Introduction to chronic hepatitis B infection [J]. Am J Gastroenterol，2006，101 Suppl 1：S1-S6.
[22] Cahir-Mcfarland ED，Carter K，Rosenwald A，et al. Role of NF-kappa B in cell survival and transcription of latent membrane protein1-expressing or Epstein-Barr virus latency Ⅲ-infected cells [J]. J Virol，2004，78（8）：4108-4119.
[23] Gentile C，Meireles-Filho AC，Britto C，et al. Cloning and daily expression of the timeless gene in Aedes aegypti （Diptera：Culicidae）[J]. Insect Biochem Mol Biol，2006，36（11）：878-884.
[24] Granfors MT，Wang JS，Kajosaari LI，et al. Differential inhibition of cytochrome P450 3A4，3A5 and 3A7 by five human immunodeficiency virus （HIV） protease inhibitors in vitro[J]. Basic Clin Pharmacol Toxicol，2006，98（1）：79-85.
[25] Saeed M，Andreo U，Chung HY，et al. SEC14L2 enables pan-genotype HCV replication in cell culture [J]. Nature，2015，524（7566）：471-475. |
|
|
|
